Gretchen Gignac, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology Section

MD, University of Pennsylvania School of Medicine



I am a medical oncologist who has clinical and research expertise in genitourinary medical oncology as well as clinical trials. My clinical practice is at Boston Medical Center and includes adult patients with cancers of the prostate, kidney, bladder, testicles and penis, as well as other solid cancers. My treatment expertise is in hormonal agents, chemotherapy, immunotherapy, targeted therapies, radioactive pharmaceuticals, bone targeted therapies, supportive and palliative care. I am also an educator in the Boston University School of Medicine and Boston Medical Center Hematology and Oncology Fellowship Program.

Active Staff Privileges
Boston Medical Center
Medicine




A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone
06/01/2011 - 11/16/2015 (PI)
Millennium Pharmaceuticals, Inc.


A Randomized phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen to Cabazitaxel/Prednisone for second line chemotherapy in men with metastatic castrte resistant prostate cance
09/28/2012 - 08/13/2015 (PI)
OncoGenex Technologies, Inc


A phase 3, Randomized, Double-blind, controlled study of cabozantinib (XL184) vs. Prednisone in Metastatic castration resistant prostate cancer patients who have received prior cocetaxel and prior abi
10/19/2012 - 10/19/2014 (PI)
Exelixis, Inc


A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.





Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Karantanos T, Karanika S, Gignac G. Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer. 2016 Sep; 23(9):691-8. PMID: 27515296; DOI: 10.1530/ERC-16-0222;.
  2. Gunnarsson O, Basaria S, Gignac GA. Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy. Cancers (Basel). 2015; 7(2):679-87. PMID: 25913100; DOI: 10.3390/cancers7020679;.
  3. Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL. Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Pract Radiat Oncol. 2011 Apr-Jun; 1(2):115-25.View Related Profiles. PMID: 24673925; DOI: 10.1016/j.prro.2010.11.007;.
  4. Ariel E. Hirsch, John J. Cuaron, Milos J. Janicek, Kit Mui, Richard J. Lee, David S. Wang, Richard K. Babayan, Ann C. Zumwalt, Gretchen A. Gignac, Wen Tao, Alexander Ozonoff, Anthony L. Zietman et al. . Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Practical Radiation Oncology. 2011; 1(2):115-125.
  5. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 May 20; 27(15):2436-42. PMID: 19364960; PMCID: PMC2684850; DOI: 10.1200/JCO.2008.20.4164;.
  6. Gignac GA, Morris MJ, Heller G, Schwartz LH, Scher HI. Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer. 2008 Sep 1; 113(5):966-74. PMID: 18661513; PMCID: PMC2708077; DOI: 10.1002/cncr.23719;.
  7. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007 Dec 1; 13(23):7053-8. PMID: 18056182.
  8. Gignac GA, Morris MJ, Hussain M. Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions. J Urol. 2007 Sep; 178(3 Pt 2):S30-5. PMID: 17644121.
  9. Vaughn DJ, Gignac GA, Meadows AT. Long-term medical care of testicular cancer survivors. Ann Intern Med. 2002 Mar 19; 136(6):463-70. PMID: 11900499.

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2007 and 2011

YearPublications
20021
20072
20081
20091
20112
20151
20161

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Project Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')


820 Harrison Ave
Boston MA 02118
Google Map


Gignac's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department